BioCardia Inc (BCDA) has released an update.
BioCardia, Inc. announced that two of its scientific abstracts, concerning its CardiAMP and CardiALLO clinical stage therapeutic programs, have been accepted for presentation at the upcoming Technology and Heart Failure Therapeutics Conference in Boston, MA on March 4-6, 2024. These abstracts will be featured in the Late-Breaking Clinical Science/First-In-Human & Early Feasibility Studies session on the first day of the conference.
For further insights into BCDA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
